HomeCompareVONE vs KMB

VONE vs KMB: Dividend Comparison 2026

VONE yields 1.14% · KMB yields 5.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KMB wins by $24.6K in total portfolio value
10 years
VONE
VONE
● Live price
1.14%
Share price
$295.12
Annual div
$3.38
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.3K
Annual income
$123.21
Full VONE calculator →
KMB
KMB
● Live price
5.25%
Share price
$96.35
Annual div
$5.06
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.9K
Annual income
$5,222.34
Full KMB calculator →

Portfolio growth — VONE vs KMB

📍 KMB pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVONEKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VONE + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VONE pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VONE
Annual income on $10K today (after 15% tax)
$97.24/yr
After 10yr DRIP, annual income (after tax)
$104.73/yr
KMB
Annual income on $10K today (after 15% tax)
$446.39/yr
After 10yr DRIP, annual income (after tax)
$4,438.99/yr
At 15% tax rate, KMB beats the other by $4,334.26/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VONE + KMB for your $10,000?

VONE: 50%KMB: 50%
100% KMB50/50100% VONE
Portfolio after 10yr
$33.6K
Annual income
$2,672.78/yr
Blended yield
7.95%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KMB right now

VONE
No analyst data
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+27.7% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VONE buys
0
KMB buys
0
No recent congressional trades found for VONE or KMB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVONEKMB
Forward yield1.14%5.25%
Annual dividend / share$3.38$5.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17%
Portfolio after 10y$21.3K$45.9K
Annual income after 10y$123.21$5,222.34
Total dividends collected$1.2K$21.6K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: VONE vs KMB ($10,000, DRIP)

YearVONE PortfolioVONE Income/yrKMB PortfolioKMB Income/yrGap
1← crossover$10,814$114.40$11,314$614.45$500.00KMB
2$11,687$115.62$12,867$760.19$1.2KKMB
3$12,622$116.78$14,713$945.27$2.1KKMB
4$13,623$117.87$16,924$1,181.90$3.3KKMB
5$14,696$118.90$19,596$1,486.64$4.9KKMB
6$15,844$119.87$22,850$1,882.16$7.0KKMB
7$17,074$120.78$26,849$2,399.80$9.8KKMB
8$18,391$121.64$31,812$3,083.36$13.4KKMB
9$19,801$122.45$38,033$3,994.72$18.2KKMB
10$21,310$123.21$45,918$5,222.34$24.6KKMB

VONE vs KMB: Complete Analysis 2026

VONEStock

Invests in stocks in the Russell 1000 Index, a broadly diversified index made up of large U.S. companies.Seeks to closely track the index’s return, which is considered a gauge of large-cap growth U.S. stock returns.Offers high potential for investment growth; share value typically rises and falls more sharply than that of funds holding bonds.More appropriate for long-term goals where your money’s growth is essential.With respect to 75% of its total assets, the fund may not: (1) purchase more than 10% of the outstanding voting securities of any one issuer or (2) purchase securities of any issuer if, as a result, more than 5% of the fund’s total assets would be invested in that issuer’s securities; except as may be necessary to approximate the composition of its target index. This limitation does not apply to obligations of the U.S. government or its agencies or instrumentalities.

Full VONE Calculator →

KMBConsumer Staples

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Full KMB Calculator →
📬

Get this VONE vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VONE vs SCHDVONE vs JEPIVONE vs OVONE vs KOVONE vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.